300 Vials Per Minute: The Pace of Progress for Catalent

Posted: Updated:
A Catalent employee inspects a vial. A Catalent employee inspects a vial.

Just 18 months after entering Indiana’s life sciences landscape, Catalent says the “red hot” biologics sector is driving the company’s repeated large investments in Bloomington. Catalent, a contract development and manufacturing organization, does business with 41 of the top 50 biotechnology companies globally. As one of Catalent’s two nerve centers for biologics, the Bloomington site is growing at a breathtaking pace; Catalent has announced $114 million worth of investments in the operation during recent months, and executives believe there could be more.

“Our site in Bloomington may require even further investment in future years to keep up with ongoing demand,” says Bernie Clark, vice president of marketing and strategy for biologics and specialty drug delivery at Catalent.

The global company, based in New Jersey, generated $2.5 billion in annual revenue in fiscal 2018. Clark says biologics is one of the fastest growing markets in pharmaceuticals and drug development, and the Bloomington facility—which Catalent acquired from homegrown Cook Pharmica in 2017—focuses solely on this cutting-edge area of medicine.

Biologics—such as vaccines, gene therapy and tissues—demand state-of-the-art technology due to their highly sensitive and complex nature. Unlike conventional drugs with simpler structures that are produced by chemical reaction, biologics may be living organisms, such as cells and tissues.  

“[Biologics] are not your typical over-the-counter tablet; these are very advanced medicines, typically focused on difficult-to-treat diseases and illnesses, ranging from cancer to cardiovascular and infectious disease,” says Clark.  

Noting “there weren’t too many facilities quite like Bloomington” in the U.S., company leaders knew the high-tech operation would be up to the task when it acquired the location from Cook Pharmica.

“At Bloomington, in particular, we work on some of the most innovative molecules, starting with cell line development,” says Clark. “We help our customers grow products inside bioreactors at high volumes before taking the purified byproducts of those cells and filling them into liquid dose forms—sterile injectables, such as vials and syringes—and finally, packaging and labeling them for distribution to patients around the globe.”

Catalent recently announced it’s pumping $100 million into the plant to meet growing demand for biologics. The plans come on the heels of an earlier announcement to invest $14 million to ramp up packaging capabilities. A new high-speed line will fill 300 vials per minute, as well as a syringe/cartridge line that will operate at the same mind-boggling pace.

The increased volume is needed for the growing operation; in the 18 months since Catalent acquired the facility, it has expanded production from 12 commercial products to 20—a 66 percent increase.

 “More than capital, people are fundamental to making that growth a success,” says Clark. “We have dozens of job openings today, and we’ll be hiring hundreds in the coming years to ramp up our operations and deliver for our customers.”

Catalent believes Bloomington’s pocket of life sciences companies, plus the proximity of Indiana University and Indianapolis, will meet its appetite for workers. Additionally, the state’s talent and workforce development initiative Ascend Indiana is working with Catalent and a handful of higher education partners to launch a project that will expand the pool of line operators for the Bloomington facility.

“To fill the magnitude of positions we’ll have open in the coming years, it’s going to take employees of all skill levels and backgrounds, from packaging and operations to lab science, to quality and engineering—across the board,” says Clark.

Of the seven U.S. facilities that comprise its biologic division, Bloomington is one of only two getting a $100 million dose of capital—the perfect medicine, says Catalent, to support the boom in biologics.

Clark says several factors are contributing to the “red hot” nature of the biologics sector.
Clark says production at the Bloomington facility relies on high-tech bioreactors.
  • Perspectives

    • Startup Spirit Fuels Growth

      As the South Bend - Elkhart Region celebrates a $42.4 million grant from Lilly Endowment Inc., we know that the work to make the best investment with it is really just beginning. The spirit of entrepreneurship has been a vibrant part of our region for decades and the story of our family company could be somewhat of a guidebook for the region as it ventures forward. ITAMCO began as a dream of my uncle Donald Neidig and my father Noble Neidig to have their own business.

    More

Subscribe

Name:
Company Name:
Email:
Confirm Email:
HTML
INside Edge
Morning Briefing
BigWigs & New Gigs
Life Sciences Indiana
Indiana Connections
INPower
Subscribe
Unsubscribe

Events



  • Most Popular Stories

    • The Waterside project aims to transform 100-acres of the former GM Stamping Plant site. (photo courtesy of Ambrose Property Group)

      Ambrose, Glick Partner on Waterside

      Indianapolis-based Ambrose Property Group has announced a key partnership for the redevelopment of the former GM Stamping Plant in downtown Indianapolis. The commercial real estate firm is teaming up with the Gene B. Glick Co. to build and manage apartments as part of the $1.4 billion mixed-use redevelopment project. Ambrose says the partnership is also part of plans to catalyze "philanthropic and community-centric strategies to strengthen Indianapolis." The firm also...

    • NIBCO is headquartered in Elkhart. (photo courtesy of NIBCO)

      Companies Detail Closures, Layoffs

      Four companies have announced plans to lay off a total of nearly 300 employees. In separate notices filed with the state, the companies say the moves will affect workers in Indianapolis, Fort Wayne, Charlestown and Peru.

    • (Rendering provided by the city of Fishers.)

      Flexware to Break Ground on Headquarters

      Fisher’s based engineering servicing firm, Flexware Innovation Inc., will break ground Thursday on its new headquarters the Nickel Plate District Amphitheater. The $3.5 million project will feature a 35,000-square-foot office building with 12,000-square feet of office space for Flexware and what it calls “a build-to-suit area” in the remaining space. 

    • (rendering courtesy of Brightmark Energy)

      Construction to Begin on Plastics-to-Fuel Plant

      California-based Brightmark Energy will today break ground on its $260 million plastics-to-fuel plant in the northeast Indiana town of Ashley. The 112,000-square-foot facility, which the company says will be the first of its kind in the nation, is expected to create 136 full-time jobs when fully operational. The plant will use a state-of-the-art process to recycle plastic waste that has reached the end of its useful life, including items that normally cannot be recycled, such as...

    • Photo courtesy of Lafayette Elementary School

      Hammond to Close Three Schools, to Cut Jobs

      The  School City of Hammond board has voted to close three schools and cut 130-150 positions. Our partners at The Times of Northwest Indiana report Columbia and Lafayette Elementary schools, and the Miller School will close after this school year.